Abstract 316P
Background
Although Olaparib has demonstrated substantial clinical benefits as maintenance therapy in BRCA mutation-carrying women with newly diagnosed advanced ovarian cancer, its effectiveness in patients without BRCA mutations remains under-investigated. This study aims to provide the first evidence on the efficacy of olaparib maintenance therapy in such a context.
Methods
Using real-world data from eleven high-volume tertiary care centers in China, we conducted a retrospective cohort study to assess the efficacy and safety of olaparib maintenance therapy in BRCA wild-type ovarian cancer patients in the first-line setting. Eligible women were identified by medical record review at each institution. The primary objective was the 1-year progression-free survival (PFS) rate. Details of safety profile were also evaluated.
Results
A total of 50 patients with a median age of 54 years were included. Of these patients, 44 (88%) had International Federation of Gynaecology and Obstetrics (FIGO) stage III disease at diagnosis, while 6 (12%) had stage IV disease. The 1-year PFS rate was 75.2% (95% CI, 63.4 to 89.2) and the median PFS was 21.0 months (95% CI, 13.8 to 28.2). All patients received olaparib at a starting dose of 300 mg twice daily and no patients experienced serious adverse events (AEs). Eight (16%) patients had a dose adjustment, but no patients discontinued olaparib treatment due to AEs.
Conclusions
We provide the first evidence that olaparib could be a safe and effective first-line maintenance treatment for women with BRCA wild-type ovarian cancer. These findings propose a new treatment option for this sizable patient subgroup.
Clinical trial identification
NCT05153603.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AZ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract